CRVS | tickerfilter.com

Fundamental analysis

22%

Profitability 0%

Dept financing 12%

Liquidity 50%

Performance 40%

Company vs Stock growth

N/A

8.690 3.930

-4.760 -54.78%

+ Add row to compare

Performance

5 Days

-1.05%

1 Month

-33.65%

3 Months

-47.09%

6 Months

-52.92%

1 Year

73.01%

2 Year

125.60%

Key data

Stock price

$2.82

P/E Ratio

0.00

DAY RANGE

$2.73 - $3.14

EPS

-$1.02

52 WEEK RANGE

$1.30 - $10.00

52 WEEK CHANGE

$86.75

MARKET CAP

343.776 M

YIELD

N/A

SHARES OUTSTANDING

62.551 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-05-2025

BETA

1.73

PUBLIC FLOAT

AVERAGE 10 VOLUME

$821,798

AVERAGE 30 VOLUME

$720,965

Company detail

CEO: Richard A. Miller
Region: US
Website: corvuspharma.com
Employees: 30
IPO year: 2016

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Corvus Pharmaceuticals, Inc. focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company was incorporated in 2014 and is based in Burlingame, California.

CRVS - Corvus Pharmaceuticals, Inc.